All In Biotech

Drug Trial Radar · NCT01294644

Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat

Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of ATX-101 (Sodium Deoxycholate Injection) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Last checked: Nov 19, 2026Latest source record: Jun 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 360 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

360

Actual

Start

Jan 2011

Primary completion

Feb 2012

Study completion Feb 2012

Sponsor

Lead sponsor
Kythera BiopharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
Bayer
First posted
Feb 11, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).

Conditions

  • Moderate or Severe Submental Fullness

Interventions

  • Deoxycholic acid injectionDrug

  • PlaceboDrug

    Phosphate buffered saline placebo for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) 1-grade ResponseTime frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)
  2. Percentage of Participants With a Subject Self Rating Scale (SSRS) ResponseTime frame: Baseline and 12 weeks after last treatment (up to 24 weeks after first dose)

Locations

29 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Geel, Belgium

  • Investigational Site

    Genk, Belgium

  • Investigational Site

    Besançon, France

  • Investigational Site

    Nice, France

  • Investigational Site

    Paris, France

  • Investigational Site

    Paris, France

  • Investigational Site

    Rouen, France

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Bochum, Germany

  • Investigational Site

    Dresden, Germany

  • Investigational Site

    Dresden, Germany

  • Investigational Site

    Erlangen, Germany

  • Investigational Site

    Freiburg im Breisgau, Germany

  • Investigational Site

    Hamburg, Germany

  • Investigational Site

    Hamburg, Germany

  • Investigational Site

    Kassel, Germany

  • Investigational Site

    Lübeck, Germany

  • Investigational Site

    Mahlow, Germany

  • Investigational Site

    Mönchengladbach, Germany

  • Investigational Site

    Münster, Germany

  • Investigational Site

    Regensburg, Germany

  • Investigational Site

    Recklinghausen, North Rhine-Westphalia, Germany

  • Investigational Site

    Roma, Italy

  • Investigational Site

    Madrid, Spain

  • Investigational Site

    Birmingham, United Kingdom

  • Investigational Site

    Cardiff, United Kingdom

  • Investigational Site

    London, United Kingdom

  • Investigational Site

    Loughborough, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.